NCT06561360 - A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 9, 2024

Primary Completion Date

September 9, 2027

Study Completion Date

September 9, 2027

Conditions

Hairy Cell Leukemia

Interventions

DRUG

Vemurafenib

Vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles.

DRUG

Obinutuzumab

Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks.

DRUG

Cladribine

Cladribine IV on days 1-5 concurrently with rituximab.

DRUG

Rituximab

Rituximab on days 1-5 concurrently with rituximab.

Trial Locations (10)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities), Commack

43210

NOT_YET_RECRUITING

Ohio State University, Columbus

55905

NOT_YET_RECRUITING

Mayo Clinic Cancer Center, Rochester

02115

NOT_YET_RECRUITING

Dana Farber Cancer Institute, Boston

07920

RECRUITING

Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale